In lung squamous cell carcinoma, Kong et al. demonstrated that treatment with the histone deacetylase inhibitor belinostat (PXD101) transcriptionally upregulates FBXO3 and FBXW10, which directly target son of sevenless (SOS), an upstream regulator of the MAPK pathway, to inhibit growth of tumor cells (Kong et al., 2017). The gene discussed is FBXO3; the disease is neoplasm.